30 March 2025
: Case report 
Andexanet Alfa in Urgent Cardiac Surgery: A Case Report of Edoxaban Reversal for Acute Hemopericardium
Unusual clinical course, Management of emergency care
Mohammad Al Mawed ABDEF 1*, Helmut Warkentin ABCDEF 2, Johannes P. Brockmeier ABDE 1, René Schramm BE 3, Jan Gummert BCDF 3, Vera von Dossow ABCD 2, Stephan Gielen ABCDE 1DOI: 10.12659/AJCR.945265
Am J Case Rep 2025; 26:e945265
Table 1. Perioperative laboratory assessment.
| Investigations | Result 23.07.2021 | Reference |
|---|---|---|
| Anti-factor Xa activity | >1.5 IU/ml | Therapeutic field 0.5–0.8 IU/ml |
| Hemoglobin | 15.5 g/dl | 12–16 g/dl |
| Platelets | 195×10/l | 150–400×10/l |
| Partial thrombin time (PTT) | 25 sec | 22–29 sec |
| International normalized ration (INR) | 1.2 | |
| Prothrombin time | 69% | 78–123% |
| Fibrinogen | 269 mg/dl | 170–420 mg/dl |
| Antithrombin III | 89% | 79–120% |
| Creatinine | 1.2 mg/dl | 0.6–1.1 |
| eGFR (MDRD formula) | 44 ml/min | >90 ml/min |
| Creatin kinase (CK) | 120 U/l | 0–145 U/l |
| Creatin kinase MB (CK-MB) | 12.1 ng/ml | 0–6.4 ng/ml |
| High-sensitive Troponin I | 552 pg/ml | 0–26 pg/ml |
| eGFR – estimated glomerular filtration rate; MDRD formula – Modification of Diet in Renal Disease formula. | ||